Skip to main content
SpringerLink
Log in

Membrane and soluble endoglin role in cardiovascular and metabolic disorders related to metabolic syndrome

  • Review
  • Published:
Cellular and Molecular Life Sciences Aims and scope Submit manuscript

Abstract

Membrane endoglin (Eng, CD105) is a transmembrane glycoprotein essential for the proper function of vascular endothelium. It might be cleaved by matrix metalloproteinases to form soluble endoglin (sEng), which is released into the circulation. Metabolic syndrome comprises conditions/symptoms that usually coincide (endothelial dysfunction, arterial hypertension, hyperglycemia, obesity-related insulin resistance, and hypercholesterolemia), and are considered risk factors for cardiometabolic disorders such as atherosclerosis, type II diabetes mellitus, and liver disorders. The purpose of this review is to highlight current knowledge about the role of Eng and sEng in the disorders mentioned above, in vivo and in vitro extent, where we can find a wide range of contradictory results. We propose that reduced Eng expression is a hallmark of endothelial dysfunction development in chronic pathologies related to metabolic syndrome. Eng expression is also essential for leukocyte transmigration and acute inflammation, suggesting that Eng is crucial for the regulation of endothelial function during the acute phase of vascular defense reaction to harmful conditions. sEng was shown to be a circulating biomarker of preeclampsia, and we propose that it might be a biomarker of metabolic syndrome-related symptoms and pathologies, including hypercholesterolemia, hyperglycemia, arterial hypertension, and diabetes mellitus as well, despite the fact that some contradictory findings have been reported. Besides, sEng can participate in the development of endothelial dysfunction and promote the development of arterial hypertension, suggesting that high levels of sEng promote metabolic syndrome symptoms and complications. Therefore, we suggest that the treatment of metabolic syndrome should take into account the importance of Eng in the endothelial function and levels of sEng as a biomarker and risk factor of related pathologies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Oujo B, Perez-Barriocanal F, Bernabeu C, Lopez-Novoa JM (2013) Membrane and soluble forms of endoglin in preeclampsia. Curr Mol Med 13(8):1345–1357

    Article  CAS  Google Scholar 

  2. Bot PT, Hoefer IE, Sluijter JP, van Vliet P, Smits AM, Lebrin F, Moll F, de Vries JP, Doevendans P, Piek JJ, Pasterkamp G, Goumans MJ (2009) Increased expression of the transforming growth factor-beta signaling pathway, endoglin, and early growth response-1 in stable plaques. Stroke 40(2):439–447. https://doi.org/10.1161/STROKEAHA.108.522284

    Article  CAS  PubMed  Google Scholar 

  3. St-Jacques S, Forte M, Lye SJ, Letarte M (1994) Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy. Biol Reprod 51(3):405–413

    Article  CAS  Google Scholar 

  4. Meurer S, Wimmer AE, Leur EV, Weiskirchen R (2019) Endoglin trafficking/exosomal targeting in liver cells depends on n-glycosylation. Cells. https://doi.org/10.3390/cells8090997

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lastres P, Bellon T, Cabanas C, Sanchez-Madrid F, Acevedo A, Gougos A, Letarte M, Bernabeu C (1992) Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 22(2):393–397

    Article  CAS  Google Scholar 

  6. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J et al (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8(4):345–351. https://doi.org/10.1038/ng1294-345

    Article  CAS  PubMed  Google Scholar 

  7. Kapur NK, Morine KJ, Letarte M (2013) Endoglin: a critical mediator of cardiovascular health. Vasc Health Risk Manag 9:195–206. https://doi.org/10.2147/VHRM.S29144

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Qu R, Silver MM, Letarte M (1998) Distribution of endoglin in early human development reveals high levels on endocardial cushion tissue mesenchyme during valve formation. Cell Tissue Res 292(2):333–343

    Article  CAS  Google Scholar 

  9. Alsamman M, Sterzer V, Meurer SK, Sahin H, Schaeper U, Kuscuoglu D, Strnad P, Weiskirchen R, Trautwein C, Scholten D (2018) Endoglin in human liver disease and murine models of liver fibrosis-A protective factor against liver fibrosis. Liver Int 38(5):858–867. https://doi.org/10.1111/liv.13595

    Article  CAS  PubMed  Google Scholar 

  10. Vicen M, Vitverova B, Havelek R, Blazickova K, Machacek M, Rathouska J, Najmanova I, Dolezelova E, Prasnicka A, Sternak M, Bernabeu C, Nachtigal P (2019) Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction in vivo and in vitro. FASEB J 33(5):6099–6114. https://doi.org/10.1096/fj.201802245R

    Article  CAS  PubMed  Google Scholar 

  11. Rossi E, Sanz-Rodriguez F, Eleno N, Duwell A, Blanco FJ, Langa C, Botella LM, Cabanas C, Lopez-Novoa JM, Bernabeu C (2013) Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigration. Blood 121(2):403–415. https://doi.org/10.1182/blood-2012-06-435347

    Article  CAS  PubMed  Google Scholar 

  12. Aristorena M, Gallardo-Vara E, Vicen M, de Las C-E, Ojeda-Fernandez L, Nieto C, Blanco FJ, Valbuena-Diez AC, Botella LM, Nachtigal P, Corbi AL, Colmenares M, Bernabeu C (2019) MMP-12, Secreted by pro-inflammatory macrophages, targets endoglin in human macrophages and endothelial cells. Int J Mol Sci. https://doi.org/10.3390/ijms20123107

    Article  PubMed  PubMed Central  Google Scholar 

  13. Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, Sier CF, ten Dijke P (2010) Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res 70(10):4141–4150. https://doi.org/10.1158/0008-5472.CAN-09-4466

    Article  CAS  PubMed  Google Scholar 

  14. Valbuena-Diez AC, Blanco FJ, Oujo B, Langa C, Gonzalez-Nunez M, Llano E, Pendas AM, Diaz M, Castrillo A, Lopez-Novoa JM, Bernabeu C (2012) Oxysterol-induced soluble endoglin release and its involvement in hypertension. Circulation 126(22):2612–2624. https://doi.org/10.1161/CIRCULATIONAHA.112.101261

    Article  CAS  PubMed  Google Scholar 

  15. Blaha M, Cermanova M, Blaha V, Jarolim P, Andrys C, Blazek M, Maly J, Smolej L, Zajic J, Masin V, Zimova R, Rehacek V (2008) Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis 197(1):264–270. https://doi.org/10.1016/j.atherosclerosis.2007.04.022

    Article  CAS  PubMed  Google Scholar 

  16. Blann AD, Wang JM, Wilson PB, Kumar S (1996) Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis 120(1–2):221–226

    Article  CAS  Google Scholar 

  17. Malhotra R, Paskin-Flerlage S, Zamanian RT, Zimmerman P, Schmidt JW, Deng DY, Southwood M, Spencer R, Lai CS, Parker W, Channick RN, Morrell NW, Elliott CG, Yu PB (2013) Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. Pulm Circ 3(2):369–380. https://doi.org/10.4103/2045-8932.110445

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Leanos-Miranda A, Navarro-Romero CS, Sillas-Pardo LJ, Ramirez-Valenzuela KL, Isordia-Salas I, Jimenez-Trejo LM (2019) Soluble endoglin as a marker for preeclampsia, its severity, and the occurrence of adverse outcomes. Hypertension 74(4):991–997. https://doi.org/10.1161/HYPERTENSIONAHA.119.13348

    Article  CAS  PubMed  Google Scholar 

  19. Doghish AS, Bassyouni AA, Mahfouz MH, Abd El-Aziz HG, Zakaria RY (2019) Plasma endoglin in Type2 diabetic patients with nephropathy. Diabetes Metab Syndr 13(1):764–768. https://doi.org/10.1016/j.dsx.2018.11.058

    Article  PubMed  Google Scholar 

  20. Rathouska J, Nemeckova I, Zemankova L, Strasky Z, Jezkova K, Varejckova M, Nachtigal P (2015) Cell adhesion molecules and eNOS expression in aorta of normocholesterolemic mice with different predispositions to atherosclerosis. Heart Vessels 30(2):241–248. https://doi.org/10.1007/s00380-014-0493-8

    Article  PubMed  Google Scholar 

  21. Nachtigal P, Zemankova Vecerova L, Rathouska J, Strasky Z (2012) The role of endoglin in atherosclerosis. Atherosclerosis 224(1):4–11. https://doi.org/10.1016/j.atherosclerosis.2012.03.001

    Article  CAS  PubMed  Google Scholar 

  22. Schoonderwoerd MJA, Goumans MTH, Hawinkels L (2020) Endoglin: beyond the endothelium. Biomolecules. https://doi.org/10.3390/biom10020289

    Article  PubMed  PubMed Central  Google Scholar 

  23. Xu G, Barrios-Rodiles M, Jerkic M, Turinsky AL, Nadon R, Vera S, Voulgaraki D, Wrana JL, Toporsian M, Letarte M (2014) Novel protein interactions with endoglin and activin receptor-like kinase 1: potential role in vascular networks. Mol Cell Proteom: MCP 13(2):489–502. https://doi.org/10.1074/mcp.M113.033464

    Article  CAS  Google Scholar 

  24. Gougos A, Letarte M (1990) Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265(15):8361–8364

    Article  CAS  Google Scholar 

  25. Llorca O, Trujillo A, Blanco FJ, Bernabeu C (2007) Structural model of human endoglin, a transmembrane receptor responsible for hereditary hemorrhagic telangiectasia. J Mol Biol 365(3):694–705

    Article  CAS  Google Scholar 

  26. Velasco S, Alvarez-Munoz P, Pericacho M, Dijke PT, Bernabeu C, Lopez-Novoa JM, Rodriguez-Barbero A (2008) L- and S-endoglin differentially modulate TGFbeta1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J Cell Sci 121(Pt 6):913–919. https://doi.org/10.1242/jcs.023283

    Article  CAS  PubMed  Google Scholar 

  27. Blanco FJ, Grande MT, Langa C, Oujo B, Velasco S, Rodriguez-Barbero A, Perez-Gomez E, Quintanilla M, Lopez-Novoa JM, Bernabeu C (2008) S-endoglin expression is induced in senescent endothelial cells and contributes to vascular pathology. Circ Res 103(12):1383–1392. https://doi.org/10.1161/CIRCRESAHA.108.176552

    Article  CAS  PubMed  Google Scholar 

  28. Conley BA, Smith JD, Guerrero-Esteo M, Bernabeu C, Vary CP (2000) Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 153(2):323–335 (S0021915000004226 [pii])

    Article  CAS  Google Scholar 

  29. Davignon J, Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 109(23 Suppl 1):III27-32

    PubMed  Google Scholar 

  30. Jerkic M, Rivas-Elena JV, Prieto M, Carron R, Sanz-Rodriguez F, Perez-Barriocanal F, Rodriguez-Barbero A, Bernabeu C, Lopez-Novoa JM (2004) Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J 18(3):609–611. https://doi.org/10.1096/fj.03-0197fje03-0197fje[pii]

    Article  CAS  PubMed  Google Scholar 

  31. Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, Husain M, Letarte M (2005) A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 96(6):684–692. https://doi.org/10.1161/01.RES.0000159936.38601.22

    Article  CAS  PubMed  Google Scholar 

  32. Santibanez JF, Letamendia A, Perez-Barriocanal F, Silvestri C, Saura M, Vary CP, Lopez-Novoa JM, Attisano L, Bernabeu C (2007) Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol 210(2):456–468

    Article  CAS  Google Scholar 

  33. Zemankova L, Varejckova M, Dolezalova E, Fikrova P, Jezkova K, Rathouska J, Cerveny L, Botella LM, Bernabeu C, Nemeckova I, Nachtigal P (2015) Atorvastatin-induced endothelial nitric oxide synthase expression in endothelial cells is mediated by endoglin. J Physiol Pharmacol 66(3):403–413

    CAS  PubMed  Google Scholar 

  34. Jerkic M, Letarte M (2015) Increased endothelial cell permeability in endoglin-deficient cells. FASEB J 29(9):3678–3688. https://doi.org/10.1096/fj.14-269258

    Article  CAS  PubMed  Google Scholar 

  35. Anderberg C, Cunha SI, Zhai Z, Cortez E, Pardali E, Johnson JR, Franco M, Paez-Ribes M, Cordiner R, Fuxe J, Johansson BR, Goumans MJ, Casanovas O, ten Dijke P, Arthur HM, Pietras K (2013) Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. J Exp Med 210(3):563–579. https://doi.org/10.1084/jem.20120662

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Rossini R, Capodanno D, Ferrero P, Gargiulo G, Capranzano P (2016) Management issues of chronic therapy with non-vitamin K oral anticoagulants or antiplatelet agents: different or alike? Int J Cardiol 221:695–696. https://doi.org/10.1016/j.ijcard.2016.07.008

    Article  PubMed  Google Scholar 

  37. Ojeda-Fernandez L, Recio-Poveda L, Aristorena M, Lastres P, Blanco FJ, Sanz-Rodriguez F, Gallardo-Vara E, de las Casas-Engel M, Corbi A, Arthur HM, Bernabeu C, Botella LM (2016) Mice lacking endoglin in macrophages show an impaired immune response. PLoS Genet 12(3):e1005935. https://doi.org/10.1371/journal.pgen.1005935

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M, Cooreman MP, Ratziu V, Langa C, Vary CP, Ramirez JR, Friedman S, Bernabeu C (2002) Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 100(12):4001–4010. https://doi.org/10.1182/blood.V100.12.4001100/12/4001[pii]

    Article  CAS  PubMed  Google Scholar 

  39. Gallardo-Vara E, Blanco FJ, Roque M, Friedman SL, Suzuki T, Botella LM, Bernabeu C (2016) Transcription factor KLF6 upregulates expression of metalloprotease MMP14 and subsequent release of soluble endoglin during vascular injury. Angiogenesis 19(2):155–171. https://doi.org/10.1007/s10456-016-9495-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C (2002) Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 277(46):43799–43808. https://doi.org/10.1074/jbc.M207160200M207160200[pii]

    Article  CAS  PubMed  Google Scholar 

  41. van Uden P, Kenneth NS, Rocha S (2008) Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 412(3):477–484. https://doi.org/10.1042/BJ20080476

    Article  PubMed  PubMed Central  Google Scholar 

  42. Henry-Berger J, Mouzat K, Baron S, Bernabeu C, Marceau G, Saru JP, Sapin V, Lobaccaro JM, Caira F (2008) Endoglin (CD105) expression is regulated by the liver X receptor alpha (NR1H3) in human trophoblast cell line JAR. Biol Reprod 78(6):968–975. https://doi.org/10.1095/biolreprod.107.066498

    Article  CAS  PubMed  Google Scholar 

  43. Csanyi G, Gajda M, Franczyk-Zarow M, Kostogrys R, Gwozdz P, Mateuszuk L, Sternak M, Wojcik L, Zalewska T, Walski M, Chlopicki S (2012) Functional alterations in endothelial NO, PGI(2) and EDHF pathways in aorta in ApoE/LDLR-/- mice. Prostaglandins Other Lipid Mediat 98(3–4):107–115. https://doi.org/10.1016/j.prostaglandins.2012.02.002

    Article  CAS  PubMed  Google Scholar 

  44. Vecerova L, Strasky Z, Rathouska J, Slanarova M, Brcakova E, Micuda S, Nachtigal P (2012) Activation of TGF-beta receptors and Smad proteins by atorvastatin is related to reduced atherogenesis in ApoE/LDLR double knockout mice. J Atheroscler Thromb 19(2):115–126

    Article  CAS  Google Scholar 

  45. Strasky Z, Vecerova L, Rathouska J, Slanarova M, Brcakova E, Kudlackova Z, Andrys C, Micuda S, Nachtigal P (2011) Cholesterol effects on endoglin and its downstream pathways in ApoE/LDLR double knockout mice. Circ J 75(7):1747–1755

    Article  CAS  Google Scholar 

  46. Rathouska J, Vecerova L, Strasky Z, Slanarova M, Brcakova E, Mullerova Z, Andrys C, Micuda S, Nachtigal P (2011) Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis. Pharmacol Res 64(1):53–59. https://doi.org/10.1016/j.phrs.2011.03.008

    Article  CAS  PubMed  Google Scholar 

  47. Alvarez-Munoz P, Mauer M, Kim Y, Rich SS, Miller ME, Russell GB, Lopez-Novoa JM, Caramori ML (2010) Cellular basis of diabetic nephropathy: V. Endoglin expression levels and diabetic nephropathy risk in patients with type 1 diabetes. J Diabetes Complicat 24(4):242–249. https://doi.org/10.1016/j.jdiacomp.2009.03.004

    Article  Google Scholar 

  48. La Sala L, Pujadas G, De Nigris V, Canivell S, Novials A, Genovese S, Ceriello A (2015) Oscillating glucose and constant high glucose induce endoglin expression in endothelial cells: the role of oxidative stress. Acta Diabetol 52(3):505–512. https://doi.org/10.1007/s00592-014-0670-3

    Article  CAS  PubMed  Google Scholar 

  49. Wang S, Hirschberg R (2009) Diabetes-relevant regulation of cultured blood outgrowth endothelial cells. Microvasc Res 78(2):174–179. https://doi.org/10.1016/j.mvr.2009.06.002

    Article  PubMed  PubMed Central  Google Scholar 

  50. Rinella ME (2015) Nonalcoholic fatty liver disease: a systematic review. JAMA 313(22):2263–2273. https://doi.org/10.1001/jama.2015.5370

    Article  CAS  PubMed  Google Scholar 

  51. Finnson KW, Philip A (2012) Endoglin in liver fibrosis. J Cell Commun Signal 6(1):1–4. https://doi.org/10.1007/s12079-011-0154-y

    Article  PubMed  Google Scholar 

  52. Garcia-Pozo L, Miquilena-Colina ME, Lozano-Rodriguez T, Garcia-Monzon C (2008) Endoglin: structure, biological functions, and role in fibrogenesis. Rev Esp Enferm Dig 100(6):355–360. https://doi.org/10.4321/s1130-01082008000600008

    Article  CAS  PubMed  Google Scholar 

  53. Meurer SK, Tihaa L, Borkham-Kamphorst E, Weiskirchen R (2011) Expression and functional analysis of endoglin in isolated liver cells and its involvement in fibrogenic Smad signalling. Cell Signal 23(4):683–699. https://doi.org/10.1016/j.cellsig.2010.12.002

    Article  CAS  PubMed  Google Scholar 

  54. Meurer SK, Alsamman M, Scholten D, Weiskirchen R (2014) Endoglin in liver fibrogenesis: bridging basic science and clinical practice. World J Biol Chem 5(2):180–203. https://doi.org/10.4331/wjbc.v5.i2.180

    Article  PubMed  PubMed Central  Google Scholar 

  55. Chan DC, Barrett HP, Watts GF (2004) Dyslipidemia in visceral obesity: mechanisms, implications, and therapy. Am J Cardiovasc Drugs 4(4):227–246

    Article  CAS  Google Scholar 

  56. Kurki E, Shi J, Martonen E, Finckenberg P, Mervaala E (2012) Distinct effects of calorie restriction on adipose tissue cytokine and angiogenesis profiles in obese and lean mice. Nutr Metab (Lond) 9(1):64. https://doi.org/10.1186/1743-7075-9-64

    Article  CAS  Google Scholar 

  57. Jilkova ZM, Hensler M, Medrikova D, Janovska P, Horakova O, Rossmeisl M, Flachs P, Sell H, Eckel J, Kopecky J (2014) Adipose tissue-related proteins locally associated with resolution of inflammation in obese mice. Int J Obes (Lond) 38(2):216–223. https://doi.org/10.1038/ijo.2013.108

    Article  CAS  Google Scholar 

  58. Vanlaere I, Libert C (2009) Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock. Clin Microbiol Rev 22(2):224–239. https://doi.org/10.1128/CMR.00047-08 (Table of contents)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Vandenbroucke RE, Libert C (2014) Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov 13(12):904–927. https://doi.org/10.1038/nrd4390

    Article  CAS  PubMed  Google Scholar 

  60. Klein T, Bischoff R (2011) Physiology and pathophysiology of matrix metalloproteases. Amino Acids 41(2):271–290. https://doi.org/10.1007/s00726-010-0689-x

    Article  CAS  PubMed  Google Scholar 

  61. Feinberg MW, Jain MK, Werner F, Sibinga NE, Wiesel P, Wang H, Topper JN, Perrella MA, Lee ME (2000) Transforming growth factor-beta 1 inhibits cytokine-mediated induction of human metalloelastase in macrophages. J Biol Chem 275(33):25766–25773. https://doi.org/10.1074/jbc.M002664200

    Article  CAS  PubMed  Google Scholar 

  62. Rajavashisth TB, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, Fishbein MC, Kaul S, Cercek B, Sharifi B, Shah PK (1999) Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 99(24):3103–3109. https://doi.org/10.1161/01.cir.99.24.3103

    Article  CAS  PubMed  Google Scholar 

  63. Rathouska J, Jezkova K, Nemeckova I, Nachtigal P (2015) Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis 243(2):383–388. https://doi.org/10.1016/j.atherosclerosis.2015.10.003

    Article  CAS  PubMed  Google Scholar 

  64. Li Q, Lin F, Ke D, Cheng Q, Gui Y, Zhou Y, Wu Y, Wang Y, Zhu P (2020) Combination of endoglin and ASCVD risk assessment improves carotid subclinical atherosclerosis recognition. J Atheroscler Thromb 27(4):331–341. https://doi.org/10.5551/jat.50898

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Saita E, Miura K, Suzuki-Sugihara N, Miyata K, Ikemura N, Ohmori R, Ikegami Y, Kishimoto Y, Kondo K, Momiyama Y (2017) Plasma soluble endoglin levels are inversely associated with the severity of coronary atherosclerosis-brief report. Arterioscler Thromb Vasc Biol 37(1):49–52. https://doi.org/10.1161/ATVBAHA.116.308494

    Article  CAS  PubMed  Google Scholar 

  66. Charytan DM, Cinelli A, Zeisberg EM (2015) Association of circulating angiogenesis inhibitors and asymmetric dimethyl arginine with coronary plaque burden. Fibrogenesis Tissue Repair 8:13. https://doi.org/10.1186/s13069-015-0029-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Blazquez-Medela AM, Garcia-Ortiz L, Gomez-Marcos MA, Recio-Rodriguez JI, Sanchez-Rodriguez A, Lopez-Novoa JM, Martinez-Salgado C (2010) Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med 8:86. https://doi.org/10.1186/1741-7015-8-86

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Bilir B, Ekiz Bilir B, Yilmaz I, Soysal Atile N, Yildirim T, Kara SP, Gumustas SA, Orhan AE, Aydin M (2016) Association of apelin, endoglin and endocan with diabetic peripheral neuropathy in type 2 diabetic patients. Eur Rev Med Pharmacol Sci 20(5):892–898

    CAS  PubMed  Google Scholar 

  69. Ekiz-Bilir B, Bilir B, Aydin M, Soysal-Atile N (2019) Evaluation of endocan and endoglin levels in chronic kidney disease due to diabetes mellitus. Arch Med Sci 15(1):86–91. https://doi.org/10.5114/aoms.2018.79488

    Article  CAS  PubMed  Google Scholar 

  70. Ceriello A, La Sala L, De Nigris V, Pujadas G, Testa R, Uccellatore A, Genovese S (2015) GLP-1 reduces metalloproteinase-14 and soluble endoglin induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Endocrine 50(2):508–511. https://doi.org/10.1007/s12020-015-0565-2

    Article  CAS  PubMed  Google Scholar 

  71. Cawyer C, Afroze SH, Drever N, Allen S, Jones R, Zawieja DC, Kuehl T, Uddin MN (2016) Attenuation of hyperglycemia-induced apoptotic signaling and anti-angiogenic milieu in cultured cytotrophoblast cells. Hypertens Pregnancy 35(2):159–169. https://doi.org/10.3109/10641955.2015.1122035

    Article  CAS  PubMed  Google Scholar 

  72. Cawyer CR, Horvat D, Leonard D, Allen SR, Jones RO, Zawieja DC, Kuehl TJ, Uddin MN (2014) Hyperglycemia impairs cytotrophoblast function via stress signaling. Am J Obstet Gynecol 211(5):e541-548. https://doi.org/10.1016/j.ajog.2014.04.033

    Article  CAS  Google Scholar 

  73. Lappas M (2014) Markers of endothelial cell dysfunction are increased in human omental adipose tissue from women with pre-existing maternal obesity and gestational diabetes. Metab Clin Exp 63(6):860–873. https://doi.org/10.1016/j.metabol.2014.03.007

    Article  CAS  PubMed  Google Scholar 

  74. Vieira MC, Poston L, Fyfe E, Gillett A, Kenny LC, Roberts CT, Baker PN, Myers JE, Walker JJ, McCowan LM, North RA, Pasupathy D, Consortium S (2017) Clinical and biochemical factors associated with preeclampsia in women with obesity. Obesity (Silver Spring) 25(2):460–467. https://doi.org/10.1002/oby.21715

    Article  CAS  Google Scholar 

  75. Coral-Alvarado PX, Garces MF, Caminos JE, Iglesias-Gamarra A, Restrepo JF, Quintana G (2010) Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure. Int J Rheumatol. https://doi.org/10.1155/2010/969383

    Article  PubMed  PubMed Central  Google Scholar 

  76. Bakouboula B, Morel O, Faure A, Zobairi F, Jesel L, Trinh A, Zupan M, Canuet M, Grunebaum L, Brunette A, Desprez D, Chabot F, Weitzenblum E, Freyssinet JM, Chaouat A, Toti F (2008) Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med 177(5):536–543. https://doi.org/10.1164/rccm.200706-840OC

    Article  CAS  PubMed  Google Scholar 

  77. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D’Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12(6):642–649. https://doi.org/10.1038/nm1429

    Article  CAS  PubMed  Google Scholar 

  78. Walshe TE, Dole VS, Maharaj AS, Patten IS, Wagner DD, D’Amore PA (2009) Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling. Arterioscler Thromb Vasc Biol 29(8):1185–1192. https://doi.org/10.1161/ATVBAHA.109.186742

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Varejckova M, Gallardo-Vara E, Vicen M, Vitverova B, Fikrova P, Dolezelova E, Rathouska J, Prasnicka A, Blazickova K, Micuda S, Bernabeu C, Nemeckova I, Nachtigal P (2017) Soluble endoglin modulates the pro-inflammatory mediators NF-kappaB and IL-6 in cultured human endothelial cells. Life Sci 175:52–60. https://doi.org/10.1016/j.lfs.2017.03.014

    Article  CAS  PubMed  Google Scholar 

  80. Kapur NK, Wilson S, Yunis AA, Qiao X, Mackey E, Paruchuri V, Baker C, Aronovitz MJ, Karumanchi SA, Letarte M, Kass DA, Mendelsohn ME, Karas RH (2012) Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation 125(22):2728–2738. https://doi.org/10.1161/CIRCULATIONAHA.111.080002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Munoz-Felix JM, Gonzalez-Nunez M, Lopez-Novoa JM (2013) ALK1-Smad1/5 signaling pathway in fibrosis development: friend or foe? Cytokine Growth Factor Rev 24(6):523–537. https://doi.org/10.1016/j.cytogfr.2013.08.002

    Article  CAS  PubMed  Google Scholar 

  82. Pannu J, Nakerakanti S, Smith E, ten Dijke P, Trojanowska M (2007) Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem 282(14):10405–10413. https://doi.org/10.1074/jbc.M611742200

    Article  CAS  PubMed  Google Scholar 

  83. Wiercinska E, Wickert L, Denecke B, Said HM, Hamzavi J, Gressner AM, Thorikay M, ten Dijke P, Mertens PR, Breitkopf K, Dooley S (2006) Id1 is a critical mediator in TGF-beta-induced transdifferentiation of rat hepatic stellate cells. Hepatology 43(5):1032–1041. https://doi.org/10.1002/hep.21135

    Article  CAS  PubMed  Google Scholar 

  84. Dituri F, Cossu C, Mancarella S, Giannelli G (2019) The interactivity between TGFbeta and BMP signaling in organogenesis, fibrosis, and cancer. Cells. https://doi.org/10.3390/cells8101130

    Article  PubMed  PubMed Central  Google Scholar 

  85. Breitkopf-Heinlein K, Meyer C, Konig C, Gaitantzi H, Addante A, Thomas M, Wiercinska E, Cai C, Li Q, Wan F, Hellerbrand C, Valous NA, Hahnel M, Ehlting C, Bode JG, Muller-Bohl S, Klingmuller U, Altenoder J, Ilkavets I, Goumans MJ, Hawinkels LJ, Lee SJ, Wieland M, Mogler C, Ebert MP, Herrera B, Augustin H, Sanchez A, Dooley S, Ten Dijke P (2017) BMP-9 interferes with liver regeneration and promotes liver fibrosis. Gut 66(5):939–954. https://doi.org/10.1136/gutjnl-2016-313314

    Article  CAS  PubMed  Google Scholar 

  86. Lawera A, Tong Z, Thorikay M, Redgrave RE, Cai J, van Dinther M, Morrell NW, Afink GB, Charnock-Jones DS, Arthur HM, Ten Dijke P, Li W (2019) Role of soluble endoglin in BMP9 signaling. Proc Natl Acad Sci U S A 116(36):17800–17808. https://doi.org/10.1073/pnas.1816661116

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Ruiz-Remolina L, Ollauri-Ibanez C, Perez-Roque L, Nunez-Gomez E, Perez-Barriocanal F, Lopez-Novoa JM, Pericacho M, Rodriguez-Barbero A (2017) Circulating soluble endoglin modifies the inflammatory response in mice. PLoS ONE 12(11):e0188204. https://doi.org/10.1371/journal.pone.0188204

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Nemeckova I, Serwadczak A, Oujo B, Jezkova K, Rathouska J, Fikrova P, Varejckova M, Bernabeu C, Lopez-Novoa JM, Chlopicki S, Nachtigal P (2015) High soluble endoglin levels do not induce endothelial dysfunction in mouse aorta. PLoS ONE 10(3):e0119665. https://doi.org/10.1371/journal.pone.0119665

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Jezkova K, Rathouska J, Nemeckova I, Fikrova P, Dolezelova E, Varejckova M, Vitverova B, Tysonova K, Serwadczak A, Buczek E, Bernabeu C, Lopez-Novoa JM, Chlopicki S, Nachtigal P (2016) High levels of soluble endoglin induce a proinflammatory and oxidative-stress phenotype associated with preserved NO-dependent vasodilatation in aortas from mice fed a high-fat diet. J Vasc Res 53(3–4):149–162. https://doi.org/10.1159/000448996

    Article  CAS  PubMed  Google Scholar 

  90. Gallardo-Vara E, Gamella-Pozuelo L, Perez-Roque L, Bartha JL, Garcia-Palmero I, Casal JI, Lopez-Novoa JM, Pericacho M, Bernabeu C (2020) Potential role of circulating endoglin in hypertension via the upregulated expression of BMP4. Cells. https://doi.org/10.3390/cells9040988

    Article  PubMed  PubMed Central  Google Scholar 

  91. Vitverova B, Blazickova K, Najmanova I, Vicen M, Hyspler R, Dolezelova E, Nemeckova I, Tebbens JD, Bernabeu C, Pericacho M, Nachtigal P (2018) Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. Atherosclerosis 271:15–25. https://doi.org/10.1016/j.atherosclerosis.2018.02.008

    Article  CAS  PubMed  Google Scholar 

  92. Dolezelova E, Sa ICI, Prasnicka A, Hroch M, Hyspler R, Ticha A, Lastuvkova H, Cermanova J, Pericacho M, Visek J, Lasticova M, Micuda S, Nachtigal P (2019) High soluble endoglin levels regulate cholesterol homeostasis and bile acids turnover in the liver of transgenic mice. Life Sci 232:116643. https://doi.org/10.1016/j.lfs.2019.116643

    Article  CAS  PubMed  Google Scholar 

  93. Nachtigal P, Pospisilova N, Vecerova L, Micuda S, Brcakova E, Pospechova K, Semecky V (2009) Atorvastatin increases endoglin, SMAD2, phosphorylated SMAD2/3 and eNOS expression in ApoE/LDLR double knockout mice. J Atheroscler Thromb 16(3):265–274

    Article  CAS  Google Scholar 

  94. Giordano A, Romano S, Monaco M, Sorrentino A, Corcione N, Di Pace AL, Ferraro P, Nappo G, Polimeno M, Romano MF (2012) Differential effect of atorvastatin and tacrolimus on proliferation of vascular smooth muscle and endothelial cells. Am J Physiol Heart Circ Physiol 302(1):H135-142. https://doi.org/10.1152/ajpheart.00490.2011

    Article  CAS  PubMed  Google Scholar 

  95. Zemankova L, Varejckova M, Dolezelova E, Fikrova P, Jezkova K, Rathouska J, Cerveny L, Botella LM, Bernabeu C, Nemeckova I, Nachtigal P (2015) Atorvastatin-induced endothelial nitric oxide synthase expression in endothelial cells is mediated by endoglin. J Physiol Pharmacol 66(3):403-413

    CAS  PubMed  Google Scholar 

  96. Shyu KG, Wang BW, Chen WJ, Kuan P, Hung CR (2010) Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta1 in cultured cardiac fibroblasts. Eur J Heart Fail 12(3):219–226. https://doi.org/10.1093/eurjhf/hfq011

    Article  CAS  PubMed  Google Scholar 

  97. Brownfoot FC, Tong S, Hannan NJ, Hastie R, Cannon P, Kaitu’u-Lino TJ (2016) Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. BMC Pregnancy Childbirth 16:117. https://doi.org/10.1186/s12884-016-0902-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Romero R, Erez O, Huttemann M, Maymon E, Panaitescu B, Conde-Agudelo A, Pacora P, Yoon BH, Grossman LI (2017) Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. Am J Obstet Gynecol 217(3):282–302. https://doi.org/10.1016/j.ajog.2017.06.003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Buda V, Andor M, Baibata DE, Cozlac R, Radu G, Coricovac D, Danciu C, Ledeti I, Cheveresan A, Nica C, Tuduce P, Tomescu MC (2019) Decreased sEng plasma levels in hypertensive patients with endothelial dysfunction under chronic treatment with Perindopril. Drug Des Devel Ther 13:1915–1925. https://doi.org/10.2147/DDDT.S186378

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Hannan NJ, Brownfoot FC, Cannon P, Deo M, Beard S, Nguyen TV, Palmer KR, Tong S, Kaitu’u-Lino TJ (2017) Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction—implications as a preeclampsia treatment. Scientific Reports 7(1):1819. https://doi.org/10.1038/s41598-017-01993-w

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Liu Y, Tian H, Blobe GC, Theuer CP, Hurwitz HI, Nixon AB (2014) Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. Invest New Drugs 32(5):851–859. https://doi.org/10.1007/s10637-014-0129-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Kumar S, Pan CC, Bloodworth JC, Nixon AB, Theuer C, Hoyt DG, Lee NY (2014) Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-beta signaling. Oncogene 33(30):3970–3979. https://doi.org/10.1038/onc.2013.386

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by project EFSA-CDN (No. CZ.02.1.01/0.0/0.0/16_019/0000841) co-funded by ERDF, Specific University Research (SVV 260 549), Charles University Grant Agency, GAUK 1130120/C, GAUK 1166119/C, and AZV CZ No. 17-31754A.

Author information

Authors and Affiliations

  1. Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Charles University, Heyrovskeho 1203, Hradec Kralove, 500 03, Czech Republic

    Matej Vicen, Ivone Cristina Igreja Sá, Katarína Tripská, Barbora Vitverová, Iveta Najmanová, Samira Eissazadeh & Petr Nachtigal

  2. Faculty of Medicine in Hradec Kralove, Department of Pharmacology, Charles University, Simkova 870, Hradec Kralove, 500 03, Czech Republic

    Stanislav Micuda

Authors
  1. Matej Vicen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ivone Cristina Igreja Sá
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katarína Tripská
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barbora Vitverová
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Iveta Najmanová
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Samira Eissazadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stanislav Micuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Petr Nachtigal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Petr Nachtigal.

Ethics declarations

Conflict of interest

No conflicts of interest, financial or otherwise, are declared by the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vicen, M., Igreja Sá, I.C., Tripská, K. et al. Membrane and soluble endoglin role in cardiovascular and metabolic disorders related to metabolic syndrome. Cell. Mol. Life Sci. 78, 2405–2418 (2021). https://doi.org/10.1007/s00018-020-03701-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00018-020-03701-w

Keywords

Search

Navigation